miR-34: from bench to bedside

Massimiliano Agostini; Richard A. Knight

doi:10.18632/oncotarget.1825

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

miR-34: from bench to bedside

Massimiliano Agostini _ and Richard A. Knight

PDF | HTML | How to cite

Oncotarget. 2014; 5:872-881. https://doi.org/10.18632/oncotarget.1825

Metrics: PDF 4767 views | HTML 5903 views | ?

Abstract

Massimiliano Agostini1 and Richard A. Knight1

1 Medical Research Council, Toxicology Unit, Leicester University, Leicester, UK.

Correspondence:

Massimiliano Agostini, email:

Keywords: microRNA, miR-34 family, cancer, therapy

Received: February 16, 2014 Accepted: March 15, 2014 Published: March 15, 2014

Abstract

The mir-34 family was originally cloned and characterized in 2007 as a p53 target gene. Almost immediately it became clear that its major role is as a master regulator of tumor suppression. Indeed, when overexpressed, it directly and indirectly represses several oncogenes, resulting in an increase of cancer cell death (including cancer stem cells), and in an inhibition of metastasis. Moreover, its expression is deregulated in several human cancers. In 2013, a miR-34 mimic has become the first microRNA to reach phase 1 clinical trials. Here we review the miR-34 family and their role in tumor biology, and discuss the potential therapeutic applications of miR-34a mimic.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1825

Publication Alerts

Reviews:

miR-34: from bench to bedside

Abstract